Cognition Therapeutics, Inc. is a clinical-stage neuroscience company developing oral medications designed to treat neurodegenerative and neuro-ophthalmic disorders
The sheer number of patients and caregivers affected by the combined burden of Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD) is the driving force behind Cognition’s mission to develop safe, effective, easy-to-administer treatment options that slow the progression of these life-altering diseases.
Cognition is advancing the development of an oral medication – CT1812 – to treat these diseases.
Lead Candidate – CT1812
CT1812 is a small molecule, oral therapeutic product candidate currently in separate Phase 2 clinical trials for the treatment of Alzheimer’s disease, DLB, and dry AMD. We believe CT1812 shows promise in protecting neurons in the brain and retina by binding to the sigma-2 receptor complex and restoring cellular damage response processes such as autophagy, cholesterol synthesis, and protein trafficking. As a potential daily oral medication, CT1812 represents a treatment paradigm shift from invasive and burdensome to convenient and comfortable.
Learn more about our ongoing and planned clinical studies here.
Learn more about our ongoing and planned clinical studies here.
Learn more about CT1812’s mechanism of action in Alzheimer’s disease